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Abstract.  The protease thrombin is a potent activator 
of various cell types. Thrombin cleaves and thereby 
activates its own seven-transmembrane-domain  recep- 
tor which couples to G  proteins.  Thrombin also can 
inhibit neuronal differentiation,  supposedly by degrad- 
ing components of the extracellular matrix.  Here we 
report that active thrombin induces immediate cell 
rounding and neurite retraction  in differentiating N1E- 
115 and  NG108-15  neural cells in serum-free culture. 
Serum (0.5-5%  vol/vol) evokes similar responses, but 
the cell-rounding and neurite-retracting  activity of 
serum is not attributable to thrombin.  Neural cell 
rounding is transient,  subsiding after 10-15 min,  and 
subject to homologous desensitization,  whereas re- 
tracted neurites rapidly degenerate.  Thrombin action is 
inhibited by cytochalasin, but not colchicine.  A novel 
14-amino acid peptide agonist of the thrombin recep- 
tor fully mimics thrombin's morphoregulatory activity, 
indicating that thrombin-induced  shape changes are 
receptor-mediated and not secondary to extracellular 
matrix degradation.  Although thrombin receptors cou- 
ple to phosphoinositide hydrolysis and Ca  2+ mobiliza- 
tion, thrombin-induced  shape changes appear to de- 
pend neither on the Ca2+/protein  kinase C- nor the 
cyclic nucleotide-mediated signal transduction path- 
ways; however, the morphological response to throm- 
bin is blocked by pervanadate,  an inhibitor of tyrosine 
phosphatases,  and by broad-specificity kinase inhibi- 
tors.  Our results suggest that the thrombin receptor 
communicates to an as-yet-uncharacterized effector to 
reorganize the actin cytoskeleton and to reverse the 
differentiated phenotype of neural cells. 
I 
N addition to having a key role in the coagulation  cas- 
cade,  the  protease thrombin  is  a  potent activator  of 
platelets  and endothelial  cells,  and a mitogen for cells 
of mesodermal origin (for example see Shuman,  1986; Car- 
ney and Curmingham,  1978; Chambard et al., 1987). Throm- 
bin  activates  its  own G  protein-coupled  receptor,  which 
spans the membrane seven times,  through a unique proteo- 
lyric  cleavage  mechanism  (Vu  et  al.,  1991). Classic  G 
protein-mediated signaling pathways in thrombin action in- 
clude  stimulation  of phosphoinositide-specific  phospholi- 
pase C,  release of arachidonic  acid,  and  pertussis toxin- 
sensitive  inhibition  of adenylate cyclase (reviewed by Siess, 
I989). Thrombin receptors also are expressed in brain (Ras- 
mussen et al.,  1991) and  are present on cultured neuronal 
cells (Snider  et al.,  1984,  1986; Snider,  1986; Means and 
Anderson 1986), while prothrombin is synthesized through- 
out the brain as well as in neural cell lines (Dihanich  et al., 
1991), suggesting that thrombin may serve a neurotransmit- 
ter or neuromodulatory function.  On the other hand, throm- 
bin can inhibit morphological differentiation of primary neu- 
ronal  cells,  astroglial,  neuroepithelial  and  neuroblastoma 
ceils (Hawkins and Seeds, 1986; Gurwitz and Cunningham, 
1988; Monard, 1988; Grand et al., 1989; Nelson and Siman, 
1990).  The mechanism  by which  thrombin  inhibits  neurite 
outgrowth remains unknown but is believed to involve pro- 
teolytic degradation  of components of the extracellular  ma- 
trix (ECM) ~ (reviewed by Monard,  1988). This hypothesis 
seems plausible since thrombin  can cleave ECM glycopro- 
teins  such  as laminin  and  fibronectin  (Liotta et al.,  1981; 
Keski-Oja et al.,  1981; Galdal et al.,  1985), molecules that 
are known for their ability to promote neurite development. 
However, the possibility that thrombin modulates neuronal 
morphology by activating its own plasma membrane recep- 
tor, rather than degrading  ECM components,  has received 
relatively  little attention. 
In  the  present  study,  we  have  investigated  the  mor- 
phoregulatory activity of thrombin in murine NG108-15 and 
N1E-115 neural cells.  These cell lines are widely used for 
studying various aspects of nerve cell function,  including the 
regulation of differentiation (for review see Nirenberg et al., 
1983; Hamprecht et al., 1985). Furthermore, N1E-115 cells 
constitute  a convenient system to investigate early signaling 
events in the proliferative  response (Moolenaar et al., 1979, 
1981, 1984).  In serum-containing  medium, these cells ex- 
press the phenotype of undifferentiated  neuroblast-like  cells, 
but they can be induced to extend neurites and to differenti- 
ate biochemically by serum  removal.  Both  N1E-I15 and 
NG108-15 cells express functional receptors and/or specific 
binding  sites  for  numerous  agonists,  including  thrombin 
1. Abbreviation used in this paper: ECM, extracellular matrix. 
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cell [Snider,  1986; Snider et al., 1986]).  Here we show that 
thrombin induces dramatic cell rounding and neurite retrac- 
tion in a time-dependent manner, with an onset within 10- 
15 s of thrombin addition. Using a newly discovered pep- 
tide agonist which duplicates the NH:-terminal "tethered" 
ligand of the receptor (Vu et al., 1991), we demonstrate that 
the rapid morphological response to thrombin is a receptor- 
mediated process and not secondary to proteolytic degrada- 
tion of the ECM.  In  addition,  we  provide evidence that 
thrombin bypasses known G protein-dependent signal trans- 
duction pathways to elicit its morphological effects. There- 
fore, we have to postulate that the thrombin receptor com- 
municates to an as-yet-unidentified  effector to reorganize the 
cytoskeleton and to reverse morphological differentiation of 
neural cells. 
Materials and Methods 
Materials 
Bovine and human thrombin, hirudin, dioctanoylglycerol, free fatty acids, 
prostaglandins, bradykinin and other neurotransmitters, colchicine, cyto- 
chalasin B, cholera toxin, 12-tetradecanoyl phorbol-13-acetate (TPA), indo- 
methacin, nordihydroguaiaretic acid, antimycin, deoxyglucose,  and vana- 
date were obtained from Sigma Chemical Co. (St. Louis, MO).  EGF and 
nerve growth factor were purchased from Collaborative Research (Lexing- 
ton, MA); PDGF and acidic FGF were gifts from C.-H. Heldin (Uppsala, 
Sweden) and M. Jaye (Rorer biotechnology, King of Prussia, US), respec- 
tively. Pertussis toxin was from List Laboratories (Campbell, CA); Indo-1 
acetoxymethylester and  NBD-phallacidin  were  from Molecular  Probes, 
Inc. (Eugene, OR), 8-Br-cGMP, 8-Br-cAMP, staurosporine, and leupeptin 
from  Boehringer  Mannheim Biochemicals  (Indianapolis,  IN),  genistein 
from Aldrich (Brussels, Belgium),  ionomycin and A23187 from Calbio- 
chem-Behring Corp. (La Jolla, CA). Pervanadate was prepared freshly by 
adding 1 mM H20~ to a 5 mM vanadate solution and incubating the mix- 
ture for 15 rain at room temperature (Fantus et al.,  1989).  Excess H202 
was removed by incubation with 200 #g/ml catalase. 
Cell Culture 
N1E-115 and NG108-15 cells were routinely grown in DME supplemented 
with penicillin (100 #g/ml), streptomycin (100 gg/ml), and 10% FCS. For 
cell rounding assays, ceils were seeded at a density of 1-2  ￿  l&/cm 2 in 
plastic 35-mm dishes. 
Cell Rounding Assay 
Before experiments, low-density cell cultures in 35-ram dishes were shifted 
to serum-free DMEM for 20-30 h. For cell rounding experiments, dishes 
were  placed  on  the  stage  of  an  inverted  microscope  (Nikon  Diaphot) 
equipped with phase-contrast optics and temperature control. Cells were 
maintained in Hepes-buffered DME at 37~  Agonists and inhibitors were 
added to the medium from concentrated stocks while the cells were ob- 
served continuously.  Experiments were documented using a Sony video- 
system (type D5CE) connected to a Sony videoprinter (type UP-850) and 
a Panasonic videorecorder (type AG-6024). 
To establish dose-response  relationships, cell morphology  was deter- 
mined semi-quantitatively at 3 rain after agonist addition. "Percent shape 
change" was defined as follows: 0%, no detectable change in morphology 
in the cell population under study (20-40 individual cells); 100%, all previ- 
ously flattened ceils in the population are fully rounded up; and 50%, all 
cells have changed morphology but are only partially ("half") rounded up. 
Other values were determined by interpolation. Data are presented as mean 
:i: SEM of experiments performed at least in triplicate. 
The kinetics of the cell rounding process was measured by a newly devel- 
oped optical method, which is based on the property that rounded cells ap- 
pear  more  bright than flattened cells when viewed  with phase-contrast 
equipment. Phase brightness was measured using a light-dependent resistor 
fitted to an eyepiece of the microscope (x 20 objective); the light-dependent 
voltage was low-pass filtered at 1 Hz and recorded on a chart recorder. No 
attempt was made to calibrate light signals in terms of cell rounding, since 
there is no simple relationship between phase brightness and cell thickness. 
Determination of[Ca2§ 
N1E-115 cells, attached to glass cover slips, were loaded with lndo-1 by ex- 
posing them  to  5  ~M  indoA  acetoxymethylester  for  30  rain at  37~ 
Fluorescence monitoring, calibration procedures, and other experimental 
details were similar to those described elsewhere (Jalink et al.,  1990). 
Microinjection of Orthovanadate 
N1E-115  cells were microinjected using glass capillary needles (tip •0.5 
#M) and an automatic pressure-driven microinjection device (Eppendorf/ 
Zeiss, Germany). The microinjected volume was estimated to be <5% of 
the cell volume. Sodium orthovanadate was dissolved in a microinjection 
buffer consisting of 100 mM K+-glutamate and 35 mM K+-citrate (pH 7.3). 
Fluorescence Microscopy 
For actin staining, ceils grown on circular coverglasses were fixed for 5 min 
with 3 % paraformaldehyde in PBS followed by permeabilization using PBS 
containing 0.1%  Triton  xq00  for  3  rain.  After  rinsing  in PBS,  NBD- 
phallacidin (2 ng/ml) was incubated with the permeabilized cells for 20 min 
at room temperature. 
Results 
Thrombin-induced Neural Shape Changes: 
a Receptor-mediated Process 
In low-density N1E-115 and NG108-15  cultures that have 
been growth-arrested for 20-24 h, >80% of the cells are flat- 
tened often with short (<30/~m) filopodia-like extensions, 
while 5-10%  of the cells have a  more fully differentiated 
morphology, showing elongated neurites (>100/~m). 3-4 d 
after serum removal all cells assume the fully differentiated 
morphology. 
Addition  of  thrombin  to  serum-deprived  N1E-115 or 
NG108-15  cells causes dramatic changes in cellular mor- 
phology (Fig. 1). Virtually every flattened cell starts to round 
up within 10-15  s of thrornbin addition, a process that is 
completed in less than a minute. Concomitantly, developing 
neurites begin to retract and growth cones collapse, followed 
by  visible  degeneration  of  shrunken  neurites  (Fig.  1). 
Thrombin-induced shape changes are dose-dependent with 
an ECs0 of ~0.1 U/ml (Fig. 2); they are completely blocked 
by hirudin (1 U/ml), a natural and highly specific thrombin 
inhibitor (Fenton, 1989) as well as by the protease inhibitor 
leupeptin (10  /~g/ml),  indicating that thrombin  action re- 
quires its proteolytic activity. 
Strikingly, a novel peptide agonist of the thrombin recep- 
tor (SFLLRRNPNDKYEPF), representing the NH2-termi- 
nus of the cleaved receptor (Vu et al.,  1991), fully mimics 
thrombin in inducing cell rounding and neurite retraction 
with an ECso of 10/~M (Fig. 2). The kinetics and maximum 
degree of peptide-induced cell rounding, as determined by 
an optical method, are indistinguishable from those induced 
by thrombin (Fig. 3). Unlike thrombin, however, the peptide 
maintains its cell-rounding and neurite-retracting activity in 
the presence of leupeptin (10/zg/ml; not shown). It thus ap- 
pears that active thrombin alters neural architecture by di- 
rectly activating its own G protein-coupled receptor rather 
than, as previously believed (Monard, 1988), by proteolyti- 
cally degrading components of the ECM. 
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that were deprived of serum for 24 h and cells were photographed at 10-s intervals as indicated. Note the apparent degeneration of shrunken 
neurites and rapid rounding up of cell bodies. Similar results were obtained with NGI08-15 cells. Bar, 50 #m. 
Serum Mimics Thrombin 
In addition to thrombin receptor agonists, we tested a variety 
of other ligands and agents for their ability to mimic throm- 
bin in causing neural  cell rounding.  Serum was  found to 
evoke shape changes very similar to those induced by throm- 
bin or peptide agonist, with half-maximal effects being ob- 
served at concentrations of 1-2 % vol/vol (Fig. 4).  In con- 
trast,  a  variety  of  neuropeptides,  neurotransmitters  and 
peptide  growth  factors,  Ca2+-ionophores,  and  protein  ki- 
nase C-activating phorbol esters all failed to affect neural 
cell shape within 20 min of their addition (Table I). 
What serum factor is responsible for neural cell rounding 
and neurite retraction? Although serum has been claimed to 
contain traces of active thrombin  (Gurwitz and  Cunning- 
ham,  1988), the following results strongly argue against a 
role for thrombin in the morphological response to serum: 
(a) pretreating serum with leupeptin (20 gg/ml) or heating 
it to 100~  (which destroys thrombin's proteolytic activity) 
does not affect serum-induced shape changes;  (b) the re- 
sponse to serum is not attenuated by hirudin (2 U/ml; results 
not shown); and (c) serum does not appear to act through the 
thrombin receptor as inferred from desensitization experi- 
ments described below. Our recent findings suggest that the 
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Figure 2. Dose-response relationships of neural shape changes in- 
duced by thrombin and a synthetic peptide, SFLLRNPNDKYEPF, 
mimicking the new amino terminus of the cleaved human receptor. 
Percent shape changes is defined as described in Materials and 
Methods. Peptide purity was >95% as revealed by HPLC analysis. 
Data are presented as mean  +  SEM. 
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Figure 4. Dose-response rela- 
tionship for FCS-indueed  NIE- 
115  shape  changes. Experi- 
mental details as described in 
the legend to Fig. 2 and in Ma- 
terials and Methods. 
shape-changing activity of serum is due, at least in part, to 
the  mitogenic phospholipid  lysophosphatidic acid,  which 
seemingly acts via an as yet unidentified receptor (van Cor- 
ven et al., 1989; Jalink, K., T. Eichholtz, E. J. van Corven, 
and W.  H. Moolenaar, manuscript in preparation). 
Reflattening and Homologous Desensitization 
In the continuous presence of thrombin or peptidc agonist, 
cells maintain their rounded shape for 10-15 min and then 
gradually become flattened again (Fig.  3), but neuritc out- 
growth remains suppressed  for prolonged periods of time 
(>8 h; not shown). After agonist removal, however, ncuritcs 
reappear after a lag period of several hours (not illustrated). 
Note that reflattened cells have a completely ditferent mor- 
phology when compared to their prestimulation shape. The 
time-dependent rdlattening of thrombin/peptide-treated ceils 
suggests that the response desensitizes. Indeed, readdition of 
peptide or thrombin to reflattened cells leaves neural cell 
morphology unaltered, whereas cells do round up again in 
response to 5 % (vol/vol) FCS (Fig. 3). These results indicate 
that thrombin receptor-mediated cell rounding is subject to 
homologous desensitization;  furthermore, they strengthen 
the notion that thrombin-induced cleavage of its receptor is 
sufficient for a  full morphological response. 
Involvement of  the Actin Cytoskeleton 
Microtubules  and  actin  microfilamcnts  are  the  major 
cytoskeletal elements regulating cell shape.  While disrup- 
tion of these structures by colchicine (10 #g/ml) and cyto- 
chalasin  B  (10  #g/ml),  respectively, did not induce rapid 
N1E-115 cell rounding, cytochalasin B completely blocked 
thrombin- and peptide-induccd cell rounding at a concentra- 
tion of 0.5/zg/rnl.  In contrast, colchicine (10 #g/ml) failed 
to  affect cell  rounding  and  neurite  retraction  (Table  I). 
Fluorescence studies using NBD-labcled phallacidin to stain 
actin filaments revealed that N1E-115 and NG108-15 cells do 
not possess well-defined "stress fibers" spanning  the cyto- 
plasm, but instead display bright actin staining in the cell pe- 
riphery only (Fig.  5).  In both flattened and rounded cells, 
actin staining is most prominent in the cell cortex  just under- 
neath the plasma membrane (Fig. 5). From these results wc 
Figure 3. Kinetics  of  thrombin and peptidc  agonist-induced shape 
changes in  NIE-II5 cells.  Cell rounding was monitored by altera- 
tions  in  emitted  light  intensity  (I)  from a small  population  of  NIE- 
115 cells  (~20 cells)  as described in Materials and Methods. T, 
thrombin  (I  U/ml); P,  peptide  (100  #M); FCS (5  % vol/vol).  Control 
peptide, LLRNPNDKYEPF (500 #M), had no effect. Traces show 
transition from a flattened state (i.e., phase-dark cells) to a fully 
rounded  state  (phase-bright cells),  a-c show cellular  morphol- 
ogy corresponding to the indicated intensity of emitted light (/). It 
should be noted that there is no simple relationship between phase- 
brightness and cell thickness. 
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Cell rounding and 
Agent  Concentration  neurite  retraction 
Thrombin 
Peptide  agonist (SFLLRNPNDKYEPF) 
Serum (fetal or newborn bovine) 
Cytochalasin B + thrombin 
Colchicine +  thrombin 
Neurotransmitters (bradykinin, carbachol, 
endothelin, histamine, serotonin, neurotensin)* 
Growth factors (EGF, PDGF, aFGF, NGF) 
Phorbol 12-myristate 13-acetate 
Dioctanoyl glycerol 
Ca  2+ ionophores (ionomycin;  A23187) 
Arachidonic acid, oleic acid 
Prostaglandins (PGE,, PGE2) 
8Br-cAMP; 8Br-cGMP* 
Forskolin 
Pertussis toxin; cholera toxinw 
Pertussis toxin + thrombin 
Cholera toxin +  thrombin 
1  U/ml  +  + 
50/~M  + + 
5 %  vol/vol  + + 
0.5  /~g/ml  +  1 U/ml 
10/xg/ml  +  1 U/ml  + + 
1-100 ~M 
200  nM 
100  ng/ml 
100  ~g/ml 
1-10 #M 
10 ~M 
2  ~M 
1 mM 
10 #M 
200 ng/ml;  10 #g/ml 
200  ng/ml  +  1 U/ml  + + 
I0/,g/ml  +  1 U/ml  ++ 
Rounding response of serum-deprived  NIE-115  cells was scored  semiquantitatively:  + +, complete rounding of >80%  of the flattened cells within 3 min;  -, 
no detectable cell rounding during a 10-rain period at 37~  Cell culture as described in Materials and Methods. aFGF, acidic FGF; NGF, nerve growth factor. 
* Neurotransmitters  were selected on basis of their ability to mimic thrombin in mobilizing Ca  2+ from internal stores in N1E-115 cells. 
:~ cAMP-raising agents (8-Br-cAMP, forskolin, cholera toxin) have no early thrombin-like effects on cell shape but tend to stimulate morphological differentiation 
upon prolonged  incubation (>30 min). 
w  Toxins were added at least 2 h before testing cellular responsiveness.  It was confirmed that both toxins were active by conventional ADP-ribosylation  assays 
(van Corven et al.,  1989 and our unpublished data). 
conclude that thrombin-induced neural shape changes are 
mediated by the cortical actin cytoskeleton, with no direct 
involvement of microtubules. 
Signal Transduction  Pathways 
Classic G protein-dependent signaling events  in thrombin 
action include stimulation of phosphoinositide hydrolysis, 
arachidonate release and pertussis toxin-sensitive inhibition 
of adenylate cyclase (e.g.,  Houslay et al.,  1986;  Rebecchi 
and Rosen, 1987; Magnaldo et al., 1988; Siess,  1989). Fig. 
6  shows  that thrombin, like the peptide agonist, evokes  a 
rapid Ca  2+ transient that precedes cell rounding; these Ca  2§ 
signals persist in the presence of EGTA (3 raM), indicating 
the release from intracellular stores (not shown). In contrast, 
Ca2+-mobilizing  neuropeptides and neurotransmitters (act- 
ing via their cognate G protein-coupled receptors) such as 
bradykinin,  carbachol,  endothelin,  histamine,  serotonin, 
neurotensin, as  well as  Ca  2+  ionophores all  fail to affect 
neural cell shape (Fig. 6 and Table I). What is more, cells 
depleted of intracellular Ca  ~+ (by addition of ionomycin in 
Ca2+-free medium)  show  a  normal  rounding  response  to 
thrombin,  despite  the  absence  of a  Ca  2+  signal (Fig.  6). 
Also, protein kinase C-activating diacylglycerol  and phorbol 
ester  leave  neural  cell  shape  unaltered  (Table  I),  while 
staurosporine,  at concentrations that preferentially inhibit 
protein kinase C (1-10 nM), did not affect the rapid morpho- 
logical effects of thrombin and peptide agonist (not shown; 
at  micromolar  concentrations,  however,  staurosporine  is 
fully inhibitory as shown below). 
Together,  these  results  indicate  that  thrombin-induced 
phospholipid hydrolysis with consequent Ca  2§ mobilization 
and protein  kinase  C  activation is  neither necessary nor 
sufficient for a morphological response. It also can be ex- 
cluded  that  thrombin-induced  shape  changes  depend  on 
effectors that  couple  to  pertussis  toxin-sensitive  G  pro- 
tein(s):  under conditions where pertussis toxin stimulates 
ADP ribosylation of G proteins in N1E-115 cells and prevents 
receptor-mediated inhibition of adenylate cyclase (van Cor- 
ven, E. J., unpublished results), we found no effect of the 
toxin on thrombin action (Table I). Furthermore, preincuba- 
tion of the cells with cyclic nucleotide-raising agents such as 
cholera toxin (10 ~g/ml), 8-Br-cAMP (1 mM), 8-Br-cGMP 
(1 mM), or forskolin (10 #M) neither mimicked nor inhibited 
the morphological response to thrombin. Also, a critical role 
for phospholipase A2 seems highly unlikely since free ara- 
chidonic acid, prostaglandins (El and E2) and potent phos- 
pholipase  A2-activating  agonists  such  as  bradykinin and 
ionomycin have no effect on cell shape, while inhibitors of 
arachidonate  metabolism  (indomethacin,  5  #M;  nordi- 
hydroguaiaretic acid, 50 #M) do not block thrombin action 
(Table I and results not shown). 
Finally, there is no apparent role for ionic transmembrane 
movements in the action of thrombin, since it was observed 
that thrombin's morphological effects were not affected by 
eliminating ionic electrochemical gradients using a 130 mM 
K-glutamate, 10 mM NaC1, 1 mM MgCI2, 0.5 mM EGTA, 
10  mM  Hepes  (pH  7.2)  incubation  buffer  (not  shown). 
Therefore,  one  is  left with  the conclusion that thrombin 
receptors bypass conventional second messenger pathways 
to alter neural architecture. 
Inhibition of Thrombin-induced Shape Changes by 
Kinase lnhibitors,  Vanadate, and ATP Depletion 
What effector of the thrombin receptor mediates the rapid 
phenotypic changes? By analogy with the cell rounding in- 
duced by active protein tyrosine kinases (Chinkers et al., 
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Figure 5. Actin  fluorescence in flattened (upper photomicrograph) 
and rounded (thrombin, 1 U/ml, lower photomicrograph) N1E-115 
cells. Cells were fixed and stained using NBD-phalloidin as de- 
scribed in Materials and Methods. Bar, 30 #m. 
1981; Jove and Hanafusa, 1987) and microinjected cdc2 ki- 
nase  (Lamb  et  al.,  1990),  it  is  plausible  to  assume  that 
specific  phosphorylations/dephosphorylations  of  certain 
actin-binding proteins (Pollard and Cooper,  1986; Stossel, 
1989) may be responsible for the morphological effects of 
thrombin. In support of this, we observed that thrombin- and 
peptide-induced shape changes are blocked by brief preincu- 
bation of the ceils with the broad-specificity protein kinase 
inhibitors genistein (Akiyama et al.,  1987)  and staurospo- 
rine (Hidaka,  1984;  Riiegg and Burgess,  1989) in a dose- 
dependent manner (Fig. 7 A); half-maximal inhibitory con- 
centrations were  ~20  /xM  for genistein  and  250  nM  for 
staurosporine. Furthermore, both microinjected orthovana- 
date, a widely used inhibitor of tyrosine phosphatases and 
exogenously added pervanadate,  which  is  the membrane- 
permeable form of vanadate (Fantus et al.,  1989), similarly 
inhibit neural shape changes (Fig. 7 B). Finally, no effects 
of thrombin were observed when cells were depleted of ATP 
by preincubation (10-15 min) with 0.1 #M antimycin and 10 
mM deoxyglucose (not shown). Direct biochemical demon- 
stration  of the presumed  kinase/phosphatase  reactions by 
which the thrombin receptor communicates to the cytoskele- 
ton awaits  further studies. 
tt  T 
Figure 6.  Ca  2§ signaling and shape changes in N1E-115 cells. Top 
traces represent typical Ca  2§ recordings from indo-l-loaded cells; 
bottom traces are from parallel cell rounding experiments. Arrows 
indicate time of addition of stimulus. T, thrombin (1 U/ml); P, pep- 
tide (100/xM); BK, bradykinin (1 t~M); E, EGTA (3 mM); i, iono- 
mycin (5/~M). Intracellular Ca  2§ concentration and cell rounding 
(l) were measured as described in Materials and Methods. Resting 
and peak Ca  2§ levels are close to 150 and 500 nM, respectively. 
Discussion 
Numerous investigations indicate that neuronal differentia- 
tion is governed by a delicate balance between positive and 
negative regulatory signals. Such diverse extracellular cues 
as ECM  components,  integrins,  neurotransmitters and se- 
creted proteases and their inhibitors can exert various effects 
on neuronal architecture, ranging from neurite extension to 
growth cone collapse and even cell death (for review see 
Dodd and Jessell,  1988; Monard,  1988; Lipton and Kater, 
1989; Doherty and Walsh,  1989;  Waiter et al.,  1990). It is 
well documented that proteolytically active thrombin can in- 
hibit long-term morphological differentiation in serum-free 
cultures of spinal cord and brain cells, neuroblastoma cells, 
astroglia  and  neuroepithelial  cells  (Hawkins  and  Seeds, 
1986;  Gurwitz  and  Cunningham,  1988;  Monard,  1988; 
Grand et al.,  1989; Nelson and Siman,  1990). Those stud- 
ies, together with recent reports that prothrombin is synthe- 
sized in the brain throughout development (Dihanich et al., 
1991), suggest that thrombin may have an important role in 
neuronal morphogenesis, development, and plasticity. The 
mechanism underlying thrombin's inhibitory effect on neu- 
ronal differentiation is not understood, although most inves- 
tigators seem to favor the hypothesis that thrombin acts by 
cleaving proteins  involved in  cell-substratum  attachment, 
thereby preventing or reversing neurite outgrowth (reviewed 
by Monard,  1988). 
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bin  receptor-mediated  shape 
changes in N1E-115 cells  by 
protein  kinase  and  tyrosine 
phosphatase  inhibitors.  (A) 
Cells were preincubated with 
the  indicated  concentrations 
of genistein and staumsporine 
for 5-10 min and then stimu- 
lated with thrombin (1 U/ml) 
for another 3 min followed by 
determination of the degree of 
cell rounding. The inhibitors 
did  not  affect  cell  viability. 
(B) Cells were preincubated 
with pervanadate (black bars) 
or microinjected with a solu- 
tion of 5 mM orthovanadate in 
injection buffer (hatched bars) 
as described in Materials and 
Methods  and  assayed for 
thrombin-induced ceil rounding as in A. It was confirmed that pervanadate was active as a tyrosine phosphatase inhibitor as follows: N1E-115 
cells treated with  100 #M pervanadate for 1-2 min showed a massive increase in tyrosine-specific phosphorylation of cellular proteins 
as measured in Western blotting experiments using an anti-phosphotyrosine antibody (Verheijden  et al., 1990 and our unpublished results). 
Exogenously added orthovanadate (0.5 mM) had no inhibitory effect (15 min preincubation). Data are presented as mean +  SEM. 
In the present study we have observed unprecedented ef- 
fects of active thrombin on the shape of serum-deprived NIE- 
115 and NG108-15 neural cells that are in their early stages 
of morphological differentiation. Thrombin not only triggers 
neurite retraction followed by disassembly within a few min- 
utes, but also causes the cell body to rapidly round up, as 
if the cells prepare for mitosis. Rounding is transient, how- 
ever, and  subject to homologous desensitization,  whereas 
neurite outgrowth remains suppressed as long as thrombin 
is present. Although growth cone collapse and neurite re- 
traction phenomena induced by external stimuli have been 
reported previously (Lipton and Kater,  1989;  Keynes and 
Cook, 1991), we are not aware of reports of similar rapid and 
dramatic changes in neural architecture as described here for 
thrombin-treated N1E-115 and NG108-15 cells under serum- 
free conditions. 
A major result of the present study is that thrombin's mor- 
phoregulatory effect is  fully mimicked by a  novel peptide 
agonist of the recently cloned thrombin receptor; this pep- 
tide, which represents the new amino terminus of the cleaved 
receptor and obviously lacks proteolytic activity, serves as 
a  tethered ligand  for the  thrombin  receptor and  is  a  full 
agonist for platelet activation (Vu et al., 1991). Together with 
the results of desensitization experiments (Fig. 3), it is clear 
that, at least in N1E-115 and NG108-15 cells, thrombin exerts 
its morphological effects by activating its own seven-trans- 
membrane-domain receptor, which couples to G  proteins, 
and  not through proteolytic attack on ECM  components. 
This does not, of  course, rule out the possibility that, in other 
cell systems, thrombin and thrombin-like proteases can mod- 
ulate cell shape via a direct action on the ECM rather than 
via receptor activation. The response to thrombin and pep- 
tide agonist is remarkably specific, in that ligands for other 
G protein-coupled receptors and peptide growth factors all 
fail to affect neural cell shape. Only serum (5-10% vol/vol) 
evokes a  morphological response that is  indistinguishable 
from that elicited by thrombin. Yet, the effect of serum is not 
attributable to serum-derived thrombin, since hirudin, leu- 
peptin, and heat inactivation have no detectable effect on the 
cell-rounding activity of serum. Identification of the serum 
factor(s) responsible for differentiation reversal remains a 
focus for further studies; as mentioned in the Results,  we 
have preliminary evidence that the morphological response 
to  serum is  attributable,  at least in  part,  to the bioactive 
phospholipid lysophosphatidate (Jalink,  K.,  T.  Eichholtz, 
E. J. van Corven, and W. H. Moolenaar, manuscript in prep- 
aration). 
An  important question concerns  the  receptor-mediated 
biochemical events underlying the morphological response 
to thrombin.  Thrombin receptor-mediated shape  changes 
appear to be due to "contraction" of the actin-based cytoskel- 
eton, with no direct role for microtubules.  Indeed, mem- 
brane-associated actin filaments, in conjunction with actin- 
binding proteins, are known not only to serve force-generating 
and structural roles in nonmuscle cells (Pollard and Cooper, 
1986;  Bray et al.,  1986;  Stossel,  1989), but also to partici- 
pate in the regulation of neurite outgrowth (Smith,  1988). 
Although  intracellular Ca  2.  has  often been regarded as  a 
key regulator of cytoskeletal reorganization in general and 
of growth cone and neurite behaviour in particular (Kater et 
al.,  1988; Lankford and Letourneau, 1989; Doherty et al., 
1991),  thrombin action appears to depend neither on Ca  2§ 
nor on other classic second messengers such as diacylglyc- 
erol and cyclic nucleotides, as outlined under Results and 
summarized in Table I and Fig. 6. We therefore have to pos- 
tulate that the thrombin receptor activates an as-yet-unchar- 
acterized effector to reorganize the actin cytoskeleton and to 
reverse neurite outgrowth. It is currently unknown whether 
multiple isoforms of the cloned thrombin receptor exist that 
may activate distinct signaling cascades. It is interesting that 
another ligand-binding member of the seven transmembrane 
domain receptor family, the yeast ct pheromone receptor, 
also evokes a  "cytoskeletal response" (mating partner dis- 
crimination) that is  independent of the known G  protein- 
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Pharmacologic  characterization  of  the  morphological 
changes suggests that the activated thrombin receptor utilizes 
vanadate-sensitive phosphatase/kinase cascades to exert its 
effects. It will be of interest to monitor the activity ofsrc-like 
protein tyrosine kinases in thrombin-treated N1E-115 cells. 
The src kinase, which is highly expressed in neuronal ceils, 
is known to be activated by vanadate-sensitive tyrosine de- 
phosphorylation (Courtneidge, 1985; Bagrodia et al., 1991) 
and is thought to act on cytoskeletal targets (Jove and Hana- 
vusa, 1987). Moreover, an important role for src-like protein 
tyrosine kinases has been implicated in the action of throm- 
bin on platelets (Huang et al.,  1991). 
At present, the precise in vivo functions of thrombin and 
its receptor(s) in the nervous system remain largely unknown. 
Apart from a normal role in neuronal morphogenesis and 
synaptic remodeling, thrombin may have a pathophysiologi- 
cal function during traumatic injury of the nervous system 
when neurons are acutely exposed to blood-borne factors 
such as thrombin and platelet-derived local mediators. One 
possibility is that, by rapidly reorganizing their cortical cyto- 
skeleton,  blood-exposed neurons  may protect themselves 
from irreversible damage and resume their normal function 
as soon as thrombolytic activity is antagonized or removed. 
Regardless of the physiological and pathophysiological func- 
tions of thrombin in the nervous system, a challenge for fu- 
ture biochemical studies is to define the sequence of events 
by which the activated thrombin receptor communicates to 
the actin-based cytoskeleton in N1E-115 and NG108-15 cells. 
After submission of this manuscript, Suidan et al. (1992) 
reported that thrombin causes neurite retraction in NB2a 
neural cells through activation of cell surface receptors. 
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